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Abstract
Background: The COVID-19 pandemic has placed an unprecedented strain on
health systems, with rapidly increasing demand for healthcare in hospitals and
intensive care units (ICUs) worldwide. As the pandemic escalates, determining
the resulting needs for healthcare resources (beds, staff, equipment) has become
a key priority for many countries. Projecting future demand requires estimates of
how long patients with COVID-19 need different levels of hospital care.
Methods: We performed a systematic review to gather data on length of stay
(LoS) of patients with COVID-19 in hospital and in ICU. We subsequently
developed a method to generate LoS distributions which combines summary
statistics reported in multiple studies, accounting for differences in sample sizes.
Applying this approach we provide distributions for general hospital and ICU LoS
from studies in China and elsewhere, for use by the community.
Results: We identified 52 studies, the majority from China (46/52). Median
hospital LoS ranged from 4 to 53 days within China, and 4 to 21 days outside of
China, across 45 studies. ICU LoS was reported by eight studies - four each within
and outside China - with median values ranging from 6 to 12 and 4 to 19 days,
respectively. Our summary distributions have a median hospital LoS of 14 (IQR:
10-19) days for China, compared with 5 (IQR: 3-9) days outside of China. For
ICU, the summary distributions are more similar (median (IQR) of 8 (5-13) days
for China and 7 (4-11) days outside of China). There was a visible difference by
discharge status, with patients who were discharged alive having longer LoS than
those who died during their admission, but no trend associated with study date.
Conclusion: Patients with COVID-19 in China appeared to remain in hospital for
longer than elsewhere. This may be explained by differences in criteria for
admission and discharge between countries, and different timing within the
pandemic. In the absence of local data, the combined summary LoS distributions
provided here can be used to model bed demands for contingency planning and
then updated, with the novel method presented here, as more studies with
aggregated statistics emerge outside China.
Keywords: Hospitalisation; ICU capacity; COVID-19; SARS-CoV-2; bed
demand; length of stay
Background
As of the April 28th 2020, there have been over 3 million confirmed cases of COVID-
19 and more than 200,000 deaths across 185 countries and territories [1]. Health
systems are challenged by the influx of patients as SARS-CoV-2, the pathogen
causing COVID-19, has spread throughout the world since its emergence in late
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December 2019 [2–6]. The risks of healthcare services being overwhelmed was most
dramatically illustrated in Italy, where a rapid increase of COVID-19 cases needing
hospitalisation pushed a well-equipped health system of 3.2 hospital beds per 1,000
people to breaking point [7]. This raises serious concerns over the potential impact
on more resource-constrained health systems in low- and middle-income countries
(LMICs) as epidemics begin to expand across Africa and South America.
Understanding and predicting hospital bed demand (as well as associated staff or
equipment requirements) provides crucial evidence for decision-making and contin-
gency planning (7,8). Predicting demand for hospital services requires an estimate
of the number of patients requiring hospitalisation, and an estimate of how long each
person will require hospital care. It is possible to model the rate of hospitalisation
in many settings based on estimated epidemic curves. However, estimating length
of stay (LoS) in hospitals requires observation of individual patient pathways.
COVID-19 presents at varying levels of severity. Hospital care can vary from
general ward based care to high dependency units with oxygen support to intensive
care where patients may be intubated for mechanical ventilation [8–10]. The LoS is
likely to depend on the level of care required, as well as the geographic setting due
to varying COVID-19 care guidelines. For example, some hospitals in China were
initially used as isolation settings [11, 12]. As knowledge of effective treatments
changes, the pathways, staff, beds and equipment required are also likely to affect
the duration and level of care needed. Moreover, patient characteristics - such as
age and comorbidities - impact disease severity [8,12–14] and are likely to influence
LoS. If differences are significant then capacity planning may need to account for
these characteristics to provide accurate predictions of the number of beds required
at each level of care. Modelling studies predicting bed occupancy published so far
have broadly relied on very few sources of information for LoS estimates, which
were often derived from very different settings [15–22]. Estimates for LoS can be
obtained from a variety of studies, but are often an incidental result rather than
a study’s primary outcome, and typically only summary statistics are reported.
In general, LoS distributions are right-skewed due to a minority of patients with
long hospital stays and are often modelled using gamma, log-normal or weibull
distributions [23] (although log-normal is less preferred due to its heavier tails).
A particular challenge is how to synthesise appropriate LoS distributions from a
range of relevant sources in similar settings, capturing the variation both within
and between them. Incorporating the uncertainty and stochasticity in parameters
using a distribution, rather than fixed point estimates (such as the mean over all
studies), allows for more realistic model predictions.
We performed a systematic review to identify the current evidence on LoS for
COVID-19 patients worldwide. We also present a method for generating LoS sum-
mary distributions by combining information from different summary statistics
(mean and medians) reported in multiple studies, and accounting for differences
in sample sizes. In doing this work, we aim to inform the efforts of modellers and
policy makers to better anticipate healthcare needs during the evolving COVID-19
pandemic.
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Methods
Search strategy
This study was conducted following the Preferred Reporting Items for Systematic
Reviews (PRISMA) guidelines(9). We searched the bibliographic databases Embase
and Medline, as well as the online preprint archive medRxiv. The latter was expected
to be an important source due to the current rapid development of this field, hence
the fully published literature would capture only a small proportion of the available
information. We included articles published up to 2020-04-12 that reported a LoS
for COVID-19 patients admitted to hospital. To ensure all relevant papers were cap-
tured, we examined the title, abstract and keywords of known studies reporting LoS
to identify relevant search terms. Our search combined the concepts of COVID-19
(Coronavirus, COVID-19, 2019-nCov and SARS-CoV-2) with search terms related
to duration of hospital stay (length of stay, admission duration, admission length,
hospital*). The search terms for hospital stay length were kept broad to capture
studies that report LoS as a secondary outcome. The full search terms for Embase,
Medline and medRxiv are presented in the supplementary materials. In addition to
our systematic searches, we also checked situation reports from the following organi-
sations to see if they reported LoS estimates: UK Intensive Care National Audit and
Research Centre (ICNARC); International Severe Acute Respiratory and Emerg-
ing Infection Consortium (ISARIC); World Health Organisation (WHO); the US
Centers for Disease Control and Prevention (CDC); and China CDC and European
CDC (ECDC).
Inclusion and exclusion criteria
Inclusion criteria:
1 Studies that reported LoS in hospital for individuals who were admitted for
confirmed COVID-19, or suspected COVID-19 which was later confirmed
2 Published (either as a pre-print or publication) between 2020-01-01 and 2020-
04-12
Exclusion criteria:
1 Studies were excluded if LoS was reported for individuals only admitted to
hospital for a reason other than confirmed or suspected COVID-19
2 Studies where the LoS endpoint was not death or discharge or continuing stay,
for example transfer to another hospital
3 Studies which stated that hospitalisation was used as a form of isolation
4 Studies not published in English
5 Review articles
Screening
The screening process is summarised in Fig. 1. All titles and abstracts were screened
independently by two reviewers (EMR and SRP). Subsequently, abstracts and full
texts of potentially relevant papers were independently reviewed by two reviewers
(EMR and YJ).
Figure 1: PRISMA diagram
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Data extraction and analysis
The data that was extracted from each study is presented in Supplementary Table
A. Data extraction was performed by EMR, YJ and ESN, and then verified by
a second member of the study team. Study characteristics (such as study dates,
study population and study design) were recorded from each study, as well as in-
formation on the LoS sample estimate for both general hospital and intensive care
units (ICUs), including sample size, discharge status and completeness of follow-
up. If multiple LoS estimates were reported for different study populations these
were all recorded (for example, LoS reported by disease severity, comorbidities and
treatment groups). One study specified non-ICU LoS and this was grouped with
general LoS estimates; ICU LoS was reported separately. Average patient age and
sex distribution (% male) were summarised across all studies by weighted mean and
standard deviation (mean (sd)), according to study sample size.
Where possible, LoS estimates were recorded as median and IQR. Otherwise, mean
and SD, or in some cases only a point estimate was provided. Where estimates were
presented as a mean, x, and standard deviation, s, we calculated the comparable
quantiles from a fitted Weibull distribution by moment-matching using the mixdist
package [24] and then discretising using the distcrete package [25] in R .
Estimating LoS distributions
Overall summary distributions were created for general hospitalisation LoS and for
ICU LoS. We included studies in the estimation of these summary distributions if
they reported both the sample size along with either the median and interquartile
range or the mean and standard deviation. If no measure of variation was provided
(either IQR or standard deviation), the point estimates were included in figures but
excluded from these summary results.
A Weibull distribution was fitted to the summary data from each grouping (by
country setting and general/ICU classification) in the appropriate studies, using
the Nelder-Mead method (using the stats package in R [26])for those reporting
medians and IQRs, and the mixdist package [24] for those reporting means and
standard deviations (as described in the previous section). The same approach was
also tested using gamma distributions, but Weibull was marginally preferred with
respect to total squared error in the fitted quantiles. These distributions were then
discretised using the distcrete package in R [25]. 100,000 samples were then drawn
from each of these distributions, with weighting according to their sample size.
Specifically, the study distributions were first sampled according to a multinomial
distribution defined by the studies’ relative sample sizes, and LoS was then sampled
from each of these sampled distributions. Due to potential important differences in
the characteristics of each study population, it may not be appropriate to weight
entirely on sample size without considering how representative the cohort is of the
general population. Therefore, as a sensitivity analysis, we performed the same
analysis without weighting in order to understand how much this influences the
distribution.
All analyses were performed using R version 3.6.3 (2020-02-29).
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Results
Study characteristics
The results of our screening process are summarised in Fig. 1. After removing dupli-
cates we found a total of 650 potentially eligible studies of which 52 studies met all
the inclusion criteria. These included 32 peer-reviewed articles from the academic
literature, 18 pre-print articles, and 2 reports from other sources ( [27] and [28]).
Several studies reported LoS by specific patient subgroups, according to disease
severity, comorbidities (kidney injury, liver injury, hypertension, and cardiac in-
jury), experimental treatments (heparin, lopinavir-ritonavir) and pregnancy status.
A complete description of all reported LoS estimates are provided in Supplementary
Table B. The key characteristics of the included studies are summarised in Table 1.
The studies were carried out between 2019-12-24 and 2020-04-16. Although the
cut-off was 2020-04-12 for inclusion of published and pre-print studies, the most re-
cent version of the ICNARC report [28] was used, which included patients admitted
up to 2020-04-16. The majority of studies were cohort studies (46/52), with four
cross-sectional studies, one case-control and one randomised control trial (RCT).
Two articles were reports from on-going data-collections (ISARIC [27], 2020-04-08,
and ICNARC [28], 2020-04-16).
Studies were mostly conducted in adults with average participant age from 19 to
76 years (mean (sd) across studies, weighted by sample size: 59 (9.6) years), and
overall reported only a slightly higher proportion of males to females (54 (10.9) %
male). Three pediatric studies included patients from newborn to 18 years, with
a weighted mean (sd) of 7 (2.8) years of age [29–31]. For the majority of studies
LoS was a secondary or incidental outcome rather than the primary outcome. As a
result, age and sex distributions were not always specific to the LoS population, and
instead reported for the overall study population. Furthermore, it was not always
possible to accurately interpret the sample size of the population, nor whether
the LoS estimate included still-hospitalised patients. All LoS data extracted from
studies are reported in Supplementary Table B.
The majority of the included studies (46/52) were based in China, with a par-
ticularly high number reported from Wuhan(27/46), and many study populations
were from the same Outside of China, there was one study from Italy [32], one for
the whole EU region [33], two from the United States [34,35], one from the United
Kingdom [28] and one study that collated LoS estimates from multiple countries
excluding China (although the majority of the data are from the UK; [27]).
Most studies (43/52) reported LoS for general hospitalisation only, with four stud-
ies reporting LoS for ICU only, and five studies reporting both. Only 15 studies
reported LoS for study populations with completed follow-up (patient discharge or
death), with 37 reporting estimates for populations where some patients remained
in hospital or in ICU. The majority of studies only included discharged or dead
patients within their LoS estimate, even if they had incomplete follow-up of the full
cohort. However, for 8 studies it was unclear whether the reported LoS included
patients who were still hospitalised [33,34,36–41].
Overall hospital length of stay
Estimates of the overall hospital LoS are summarised in Fig. 2. Where provided,
the overall study estimate of LoS for each discharge status is presented. For three
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studies, LoS was only reported within specific patient subgroups (relating to cardiac
injury [42], COVID-19 recovery trajectory [43] and treatment comparison arms [44]),
therefore in these cases we include both estimates. The longest stays were recorded
in a study of five critically ill patients [45], of whom only three were discharged and
all more than 50 days after admission, which does not appear representative of the
overall distribution (see Fig. 2, Shen et al. (2020-01-20)). Excluding this study, the
median duration of hospitalisation ranged from 5 to 29 days. There was no observed
trend with respect to when the study was conducted (Fig 2).
Estimates for LoS amongst patients who died in hospital were generally shorter
than those for patients who were discharged alive, with medians between 4 and 21
days compared to 4 and 53 days, respectively. This difference is apparent in Fig. 2,
where median LoS was lower for those discharged alive in 6 out of 8 studies that
reported both outcomes. In studies that reported general hospital LoS by disease
severity (11 studies, Supplementary Fig. A), there was a trend towards more severe
cases having longer LoS. However, the definition of different levels of severity was
inconsistent between studies so it is not possible to draw any confident conclusion.
Visual inspection of the study estimates suggested some evidence of a difference
between general hospital LoS reported within and outside China, but studies outside
China were too few (5/48) for a formal comparison. However, LoS reported within
the ISARIC report [27] in particular (which includes contributed data from 25
countries, but with the majority of patients from the UK) gave a median and IQR
(4 days (1 - 9)) substantially lower than the weighted mean from the studies from
China (15.3 days).
The patient populations observed in these studies covered a wide range of ages,
including three pediatric studies [29–31]. Among patients discharged alive there
appears to be little difference in average LoS between studies with the youngest
and oldest patients, but the longest estimates came from studies with average age
in the upper end of the range (Wang et al. [39] and Shi et al. [44], with average
age of 68 and 69, respectively; Supplementary Fig. B). The LoS estimates which
included non-survivors tended to come from studies with older populations, as is to
be expected given the well-documented, age-dependent fatality rate [46].
ICU length of stay
Median stay in ICU ranged from 5 (IQR 2 - 9) to 19 (No IQR reported) days. There
appeared to be less of a difference according to discharge status (alive or dead) than
there was for general LoS (Fig. 3). A total of 8 studies reported ICU LoS estimates,
with the same number of studies reporting LoS estimates from China and outside
of China, and the resulting overall estimates are very similar. There were too few
studies to conduct any comparison by age or disease severity.
Figure 3: ICU stay estimates
Estimated distributions
Estimated summary hospital LoS distributions for studies from China and studies
outside China are shown in Fig. 4. The median and IQR for general hospital was
estimated to be 14 (10-19) for China and 5 (3-9) excluding China. This was also
repeated for ICU LoS, with a median and IQR 8 (5-13) for China and 7 (4-11)
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outside China. Studies from China which had complete follow-up with respect to
general hospital LoS were compared with studies with incomplete follow-up. A slight
difference was observed, with shorter median LoS observed in studies with complete
follow-up (median, 12; IQR 8 -17) compared with incomplete follow-up (median, 14;
IQR, 10-19; Supplementary Fig. C). This was only performed for general hospital
LoS in China, since no studies from outside China reported completed LoS for ICU.
For general hospital LoS in China, five studies were not included since they only
provided point estimates for the LoS. The point estimates from four of these studies
fell within the IQR of the estimated distribution, however, for [45], the point esti-
mate was much longer. For general LoS outside of China, one study reported only
a point estimate [33], and this also fell outside of the estimated IQR. Sensitivity
analysis showed that weighting by sample size had minimal influence on the shape
of these distributions (Supplementary Fig. D).
Figure 4: Summary distributions
Discussion
Summary of findings
Understanding how long patients hospitalised with COVID-19 remain in hospital
is critical for planning and predicting bed occupancy as well as associated staff and
equipment needs. This review found that hospital LoS observations for COVID-19
patients published in the literature to date varied from less than a week to nearly two
months. Stay in intensive care was shorter and less variable, with studies reporting
medians of one to three weeks. Where LoS was reported according to discharge
status, stay was found to be shorter for those who died than for those discharged
alive; however, this difference was only apparent in terms of overall stay and not stay
in ICU (no statistical comparison was made). With respect to practical implications,
knowledge of a difference between survivors and non-survivors is of less use since
the outcome will not be known in advance in order to influence decision-making.
To the authors’ knowledge, this is the first formal review that has been conducted
on hospital LoS for COVID-19.
The included studies yield some evidence of a difference between total hospital
LoS observed in China and outside of China, with shorter LoS reported in the latter
group (14 days (10-19) versus 5 days (3-9), respectively). However, only five studies
were identified which reported LoS outside of China therefore this comparison is
somewhat inconclusive. It may be that LoS is longer in China compared with other
settings due to different criteria for hospital admission and discharge. A consensus
exists across guidelines, such as ensuring resolution of symptoms and evidence of
two negative PCR samples at least 24 hours apart before discharge [47,48], however,
differences between settings may arise as a result of local capacity and strain on
the health system. We attempted to capture this difference by recording time from
onset of symptoms to admission, however, only one study outside of China reported
this and a comparison was not possible. It is also possible that, with foresight from
witnessing the Chinese epidemic, other countries set less strict criteria for discharge,
in anticipation of stretched capacity. Other countries may also have used evidence
from China to improve treatment methods and hence shorten LoS. However, this
unfortunately appears unlikely as we did not observe a trend when looking at the
reported LoS estimates over time.
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In contrast, no difference was observed between settings for ICU LoS, for which
there were an equal number of studies included from within and outside China. It
is important to note that there might be key differences between ICUs in China
compared with other countries, yet a definition for what constituted an ICU was
rarely reported. Previous studies have found that ICU characteristics varied widely
across geographic regions [49]. Further understanding of characteristics of ICUs
reporting LoS for patients with COVID-19 are important in providing context on
the reported estimates and should be investigated in future studies.
There appeared to be little difference of LoS observed by age in our results,
apart from the fact that studies which reported deaths tended to have older patient
populations. However, if there is indeed a trend we were unlikely to observe strong
evidence for it amongst these studies, since the majority include a similar mix of
ages, often tending towards older cohorts, and the age distribution was not always
provided for the specific subgroup who had LoS recorded. Two studies [27,38] were
included in the review which reported LoS by age, and they both found longer LoS
associated with older age groups. In addition, a study of LoS from the USA which
was published after the search dates also reported a trend for longer LoS in older
age groups [50].
Limitations and biases
Having been the first country to observe this novel coronavirus, published data on
COVID-19 patient outcomes in China is more widely available than from countries
to which the epidemic spread later on. The set of studies found in this review
reflects this bias towards evidence obtained from China, particularly Wuhan. As
more studies emerge from a broader range of settings it would be important to
re-evaluate LoS estimates, as there are likely to be between-country differences that
we have not captured here.
Furthermore, a number of studies include patients from the same hospital over
the same period, for example, Yang et al. [51] and Wu et al. [52] who both reported
patients from Jin Yin Tan hospital in Wuhan), and it is possible that these studies
had overlapping study populations. Furthermore, Guan et al. [36] was a national
study conducted in China and ISARIC [27] included 25 countries world-wide, there-
fore these studies may also include patients previously described. The effect of this
double-counting would be to bias the summary statistics towards the LoS from
these settings. Although this is acknowledged as an issue, this was not considered
as an exclusion criteria as it would have resulted in the exclusion of many studies.
The overall benefit of inclusion was deemed to out-weigh the potential biases which
may arise as a result of overlapping patient populations.
In this review we were only able to distinguish between “general hospital LoS”
and “ICU LoS”, with many studies only reporting an overall LoS. This overall
LoS will include both general hospital and ICU admissions within it. There is a
need for more granularity with respect to patient pathways, distinguishing between
admissions to different levels of care within one hospital episode in order to better
inform healthcare contingencies. Patients may, for example, be transferred to ICU
on more than one occasion during their stay, which is important to factor in when
ICU capacity is particularly limited.
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Changes in hospital demand may have also affected our estimates. At the begin-
ning of the outbreak and in certain settings, hospitals were being used to isolate
patients who were unable to isolate effectively at home [11,12]. This means that LoS
for patients in some of the earlier studies within this dataset could have been longer
due this logistical reason, rather than clinical need. Studies which mentioned this
explicitly were excluded, yet there may still be others which were not so transparent.
In addition, it is possible that, as hospitals reach the limits of their capacity, a more
stringent triage policy may be implemented and the most critical patients may not
be transferred to ICU. Despite this, we did not observe a trend when looking at the
reported LoS estimates over time, suggesting that this is not in fact an important
issue in our data.
Finally, many studies had incomplete follow-up with respect to LoS and, as a
result, patients still hospitalised at the end of the study were not included in the
summary statistics (right-truncation). This will bias estimates towards shorter LoS,
as patients with longer LoS will not be included. A study by Lapidus et al. [53]
investigated the bias associated with estimating average ICU LoS for COVID-19
patients based on observed LoS of discharged patients before follow-up of the entire
patient cohort was completed. As expected, the authors found that the average LoS
estimated at three months of follow-up was much longer than that estimated at
one month. This potentially affects our estimates, given that 37 (out of 52) studies
had incomplete follow-up with regards to LoS; although on comparison the differ-
ence between the groups was slight, and estimates where follow-up was complete
were overall shorter. Several studies included still-hospitalised patients in their LoS
summary without accounting for censoring [33, 34, 36–41], which potentially alters
interpretation of the values.
Summarising length of stay
We found that LoS is often not the primary measure of interest in studies which
report it, however it is an important parameter when it comes to forecasting bed
occupancy during an outbreak. By conducting this review we have systematically
gathered a range of published estimates, providing a source from which researchers
and decision makers can obtain estimates specific to their population of interest
(e.g. with respect to comorbidities) and allowing comparison of LoS between several
different populations and settings.
There have been numerous previous studies which have aimed to forecast the
number of hospital beds required for COVID-19 patients [16–22,54]. Many of these
studies published so far have used point estimates, only originating from one study
which often does not reflect the context of interest. In particular, many used esti-
mates from Zhou et al. [55] which reported a shorter general hospital LoS (median
11·0, IQR 7·0–14·0; Fig. 2), and a comparable ICU LoS (median 8·0, IQR 4·0–12·0;
Fig. 3), compared with other studies from China. However, both of these were still
longer than LoS estimates reported by studies outside of China. This means that
the bed-forecasting studies relying on LoS estimates from Zhou et al. may be over-
estimating the number of beds required. The LoS estimate is a critical parameter
within a bed forecasting model, and as such any model is likely to be very sensitive
to the value or distribution being assumed, with huge implications for policy and
planning.
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This review has highlighted several potential sources of variation in LoS, and
identified common issues and biases which influence each individual estimate. This
gives a motivation for considering a wider range of values than can be obtained in
a single study, aiming instead to capture the overall distribution of LoS across a
variety of possible patient trajectories. Here we have included estimates of the overall
LoS distribution in two settings (China/Other) for which we obtained sufficient
data.
It is preferable to use data from the setting for which you are trying to forecast
bed occupancy (as was done by the IHME COVID-19 health service utilization
forecasting team [15]), however data on completed patient stays will often not be
available until well after the onset of the epidemic. Furthermore, LMICs may have
reduced capacity for surveillance and monitoring in order to obtain these data. In
such cases, where countries are in the early stages of an outbreak, it would be better
to use a conservative (i.e broad) distribution of LoS from another setting. As the
pandemic progresses and more countries observe patients completing their hospital
episodes, it will be possible to add further setting-specific summaries and improve
this distribution.
As far as the authors are aware, the approach demonstrated here to summarise
median and IQRs across multiple studies has not been proposed before, although
there are similarities with the approach taken by others in the CMMID Working
Group to pool R0 estimates [56]. We present an intuitive method which exploits two
optimisation methods to fit parametric distributions based on reported summary
statistics rather than individual data, then samples across them. In this way we
capture the central tendency and overall variation between a set of quantiles from
different study populations. This allows multiple sources of evidence to be consoli-
dated into a single distribution which can be used in bed forecasting going forward.
By providing both the code for this analysis and our summary distributions, better
bed occupancy predictions can be made in the future.
Conclusion
This review summarised the available literature to provide estimates of LoS for
general admission and ICU which can be applied for planning and preparedness for
SARS-CoV-2. We found substantial differences between China and other settings
in terms of total hospital stay, but little evidence for an impact on LoS of time
of study, age or disease severity. We present summary distributions which can be
used within models making predictions about bed requirements, and suggest that
this may be a more robust and realistic way to characterise LoS than relying on
summary data from just one setting or hospital. The majority of the data presented
in this review comes from China and, as more data become available, it will be
important to update this with setting-specific LoS estimates. Understanding the
duration of hospitalisation of COVID-19 patients is critical for providing insights as
to when hospitals will reach capacity, as well predicting associated staff or equipment
requirements.
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Figures
Figure 1 PRISMA diagram showing the results of the screening process used to identify included
studies (n = 52).
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Figure 2 Hospital length of stay, by discharge status. Medians (square) are presented with
interquartile range (IQR). Where estimates were reported as mean and standard deviation,
equivalent quantiles have been calculated assuming a Weibull distribution (triangle); if no measure
of variation was reported, only the original mean is presented (circle). The grey dashed lines
represent the mean value across all point estimates within that setting, weighted by sample
size.The studies are ordered by the study start date, with most recent at the top. Two studies
(Shi et al. (2020-02-02) and Shi et al. (2020-01-23)) have multiple estimates for the same
outcome which represent multiple treatment and comorbidity subgroups, respectively. Details of
these are included in Table 1.
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Figure 3 ICU length of stay, by discharge status. Medians (square) are presented with
interquartile range (IQR). Where estimates were reported as mean and standard deviation,
equivalent quantiles have been calculated assuming a Weibull distribution (triangle); if no measure
of variation was reported, only the original mean is presented (circle). The grey dashed lines
represent the mean value across all point estimates within that setting, weighted by sample size.
Studies are ordered by the study start date.
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Figure 4 Combined LOS distributions. Samples from the overall LoS distributions, split by
location (China or rest of world) and type (ICU vs General). For each subset, 100000 draws were
taken. The x-axis was cut at days = 60.
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